Overview

EARly Prevention of aTHeroma Progression

Status:
Terminated
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare standard therapy (risk factor control, life style modification) versus standard therapy plus low-dose rosuvastatin therapy (5mg/day) on progression of coronary atherosclerosis in statin naive individuals who have mild CAD (nonobstructive coronary atherosclerotic plaques) and normal LDL (low-density lipoprotein) cholesterol levels(<130mg/dl).
Phase:
Phase 4
Details
Lead Sponsor:
CHEOL WHAN LEE, M.D., Ph.D
Collaborator:
CardioVascular Research Foundation, Korea
Treatments:
Rosuvastatin Calcium